These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 277166)

  • 21. [Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy].
    Hetzel GR; Heering P; Grabensee B
    Med Klin (Munich); 1999 Oct; 94(10):549-55. PubMed ID: 10554513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AL amyloidosis: therapeutic response in two patients with renal involvement.
    Goddard IR; Jackson R; Jones JM
    Nephrol Dial Transplant; 1991; 6(8):592-4. PubMed ID: 1956560
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination chemotherapy for primary amyloidosis reconsidered.
    Cohen HJ
    Ann Intern Med; 1978 Oct; 89(4):572-3. PubMed ID: 697241
    [No Abstract]   [Full Text] [Related]  

  • 25. [Follicular mucinosis with generalized para-amyloidosis as a cutaneous paraneoplastic syndrome in myeloma (IgD and light chain plasmacytoma). A demonstration of the course using melphalan-prednisone therapy with a 3 years remission].
    Jänner M; Lippert HD; Stolzenbach G
    Z Hautkr; 1977 Aug; 52(16):873-40. PubMed ID: 408988
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.
    Sanchorawala V; Seldin DC; Berk JL; Sloan JM; Doros G; Skinner M
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):469-72. PubMed ID: 21156464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of primary amyloidosis.
    Lancet; 1978 Dec; 2(8101):1187-8. PubMed ID: 82148
    [No Abstract]   [Full Text] [Related]  

  • 28. Amyloidosis.
    Cohen AS; Jones LA
    Curr Opin Rheumatol; 1991 Feb; 3(1):125-38. PubMed ID: 2043438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary cardiac amyloidosis with 20-year survival.
    Fealey ME; Edwards WD; Grogan M; Dispenzieri A
    Cardiovasc Pathol; 2006; 15(6):331-5. PubMed ID: 17113011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current treatment of AL amyloidosis].
    Kovacsovics T
    Rev Med Suisse Romande; 2000 Oct; 120(10):771-5. PubMed ID: 11109905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resolution of amyloidosis and plasma-cell dyscrasia with combination chemotherapy.
    Corkery J; Bern MM; Tullis JL
    Lancet; 1978 Aug; 2(8086):425-6. PubMed ID: 79787
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
    Breems DA; Sonneveld P; de Man RA; Leebeek FW
    Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Primary amyloidosis associated to severe factor X deficiency].
    Pérez Martínez J; Llamas F; López Montes A; Massó P; Poblet E; López Rubio E; Gallego E; Gómez Roldán C
    Nefrologia; 2004; 24(5):493-8. PubMed ID: 15648909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients.
    Rysavá R; Merta M; Spicka I; Tesar V
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v38-40. PubMed ID: 12817067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary systemic amyloidosis with delayed progression to multiple myeloma.
    Rajkumar SV; Gertz MA; Kyle RA
    Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
    Mohri H
    Am J Hematol; 2004 Dec; 77(4):421-2. PubMed ID: 15551292
    [No Abstract]   [Full Text] [Related]  

  • 37. An unusual case of primary systemic amyloidosis.
    Ambrosone L; Mansi L; Salvatore T; Marino F; Orabona P; Rambaldi A; Rambaldi PF; Rambaldi M
    J Eur Acad Dermatol Venereol; 1998 Jan; 10(1):53-7. PubMed ID: 9552758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.
    Leung N; Slezak JM; Bergstralh EJ; Dispenzieri A; Lacy MQ; Wolf RC; Gertz MA
    Am J Kidney Dis; 2005 Jan; 45(1):102-11. PubMed ID: 15696449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.